Author: Melissa Pozotrigo, PharmD, BCOP Is Shorter Duration Therapy Less Effective Than Indefinite Maintenance? The phase 3 ENDURANCE (E1A11) trial provides compelling evidence regarding the duration of lenalidomide maintenance in patients with standard-risk, newly...
Author: Melissa Pozotrigo, PharmD, BCOP Minimal residual disease (MRD) testing has become one of the most important advances in cancer care over the past twenty years. It can find very small amounts of remaining disease that standard methods such as blood tests,...
